➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
Medtronic
McKinsey
Express Scripts

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,216,176


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,216,176
Title:Abuse resistant drug formulation
Abstract: A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
Inventor(s): Habib; Walid A. (Riyadh, SA), Hamed; Ehab (Concord, MA), Vega Zepeda; Manuel A. (Minnetonka, MN)
Assignee: Cima Labs Inc. (Brooklyn Park, MN)
Application Number:14/714,854
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 9,216,176

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-001 Jan 17, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-002 Jan 17, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-003 Jan 17, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-004 Jan 17, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-005 Jan 17, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,216,176

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2663172   Start Trial
Canada 2699142   Start Trial
Cyprus 1115005   Start Trial
Cyprus 1116598   Start Trial
Denmark 2073795   Start Trial
Denmark 2200593   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
Merck
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.